Specific TCR or BCR clonotypes that expand in response to tumor-expressed AQP4 could be developed into highly sensitive assays not just for monitoring NMOSD activity, but for detecting an occult cancer and monitoring its eradication following therapy. The gene discussed is AQP4; the disease is cancer.